The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Overview
Biophysics
Cell Biology
Molecular Biology
Authors
Affiliations
The tumor microenvironment (TME) includes a network of cancerous and non-cancerous cells, together with associated blood vessels, the extracellular matrix, and signaling molecules. The TME contributes to cancer progression during various phases of tumorigenesis, and interactions that take place within the TME have become targets of focus in cancer therapy development. Extracellular vesicles (EVs) are known to be conveyors of genetic material, proteins, and lipids within the TME. One of the hallmarks of cancer is its ability to reprogram metabolism to sustain cell growth and proliferation in a stringent environment. In this review, we provide an overview of TME EV involvement in the metabolic reprogramming of cancer and stromal cells, which favors cancer progression by enhancing angiogenesis, proliferation, metastasis, treatment resistance, and immunoevasion. Targeting the communication mechanisms and systems utilized by TME-EVs is opening a new frontier in cancer therapy.
Forte D, Pellegrino R, Falvo P, Garcia-Gonzalez P, Alabed H, Maltoni F Nat Commun. 2024; 15(1):10878.
PMID: 39738118 PMC: 11685939. DOI: 10.1038/s41467-024-55231-9.
Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities.
Espiau-Romera P, Gordo-Ortiz A, Ortiz-de-Solorzano I, Sancho P Extracell Vesicles Circ Nucl Acids. 2024; 5(3):455-470.
PMID: 39697624 PMC: 11648520. DOI: 10.20517/evcna.2024.12.
Recent progress of principal techniques used in the study of Müller glia reprogramming in mice.
Yin Z, Kang J, Xu H, Huo S, Xu H Cell Regen. 2024; 13(1):30.
PMID: 39663301 PMC: 11635068. DOI: 10.1186/s13619-024-00211-z.
Extracellular vesicles in cancers: mechanisms, biomarkers, and therapeutic strategies.
Ma Y, Zhang X, Liu C, Zhao Y MedComm (2020). 2024; 5(12):e70009.
PMID: 39611045 PMC: 11604295. DOI: 10.1002/mco2.70009.
The signature of extracellular vesicles in hypoxic breast cancer and their therapeutic engineering.
Zhu B, Xiang K, Li T, Li X, Shi F Cell Commun Signal. 2024; 22(1):512.
PMID: 39434182 PMC: 11492701. DOI: 10.1186/s12964-024-01870-w.